Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023 By: Taro Pharmaceutical Industries Ltd. via Business Wire June 30, 2023 at 09:00 AM EDT Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to William.Coote@taro.com Additionally, the report may be accessed on the SEC’s website at www.sec.gov. **** Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at www.taro.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230630387986/en/Contacts William J. Coote VP, CFO (914) 345-9001 William.Coote@taro.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023 By: Taro Pharmaceutical Industries Ltd. via Business Wire June 30, 2023 at 09:00 AM EDT Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to William.Coote@taro.com Additionally, the report may be accessed on the SEC’s website at www.sec.gov. **** Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at www.taro.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230630387986/en/Contacts William J. Coote VP, CFO (914) 345-9001 William.Coote@taro.com
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to William.Coote@taro.com Additionally, the report may be accessed on the SEC’s website at www.sec.gov. **** Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at www.taro.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230630387986/en/